Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11651609 | 0.87 | KDM4E (0.45) | KDM4ESMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL1491062 | 0.85 | MEN1 (0.49) | KDM4ETSHRLMNAKMT2AALDH1A1 | |
| SCHEMBL1491073 | 0.79 | KDM4E (0.46) | KDM4ESMN1; SMN2TSHRLMNAALDH1A1 | |
| SCHEMBL1491059 | 0.79 | NPBWR1 (0.48) | CYP1A2KDM4ETSHRLMNAKMT2A | |
| SCHEMBL1491082 | 0.78 | APLNR (0.50) | KDM4ESMN1; SMN2TSHRLMNAALDH1A1 | |
| SCHEMBL1491095 | 0.78 | KDM4E (0.53) | KDM4EKMT2AALDH1A1PKMMEN1 | |
| SCHEMBL1493412 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1PKM | |
| SCHEMBL1491063 | 0.75 | MAPT (0.44) | KDM4ESMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL28863558 | 0.75 | KDM4E (0.43) | KDM4EKMT2AALDH1A1PKMDHFR | |
| SCHEMBL1491108 | 0.75 | LMNA (0.55) | KDM4EAOC3SMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152208-B1 | PYRIMIDO[4,5-B]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES AS SUPPRESSORS OF NON-SENS MUTATIONS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| EP-3152208-B1 | PYRIMIDO[4,5-B]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES AS SUPPRESSORS OF NON-SENS MUTATIONS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9896448-B2 | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896448-B2 | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896448-B2 | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170183341-A1 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170183341-A1 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170183341-A1 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| EP-3152208-A1 | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES | Novartis AG (CH) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015186062-A1 | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-10 | — | — | WO | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183341-A1 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives | QDPR, IL5, CYP3A5 | CHRM2 1886/4885OPRK1 250/4885CYP1A2 97/4885 |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CHRM2 230/4885OPRK1 82/4885CYP1A2 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.